The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Timeframe: Up to Day 29 (7 days after each injection)
Number of Participants with Unsolicited Adverse Events (AEs)
Timeframe: Up to Day 43 (21 days after each injection)
Number of Participants with AEs Leading to Discontinuation From Study
Timeframe: Day 1 to Day 205 (end of study [EoS])
Number of Participants with Medically-Attended AEs (MAAEs)
Timeframe: Day 1 to Day 205 (EoS)
Number of Participants with Serious Adverse Events (SAEs)
Timeframe: Day 1 to Day 205 (EoS)
Number of Participants with Adverse Events of Special Interest (AESIs)
Timeframe: Day 1 to Day 205 (EoS)